Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Design for sample size re-estimation with interim data for double-blind clinical trials with binary outcomes

W J Shih1, P L Zhao

  • 1Merck Research Laboratories, Rahway, New Jersey 07065, USA.

Statistics in Medicine
|September 26, 1997
PubMed
Summary

This study introduces a new method for estimating sample sizes in clinical trials with binary outcomes. It allows for sample size re-estimation using interim data while maintaining trial blinding.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Association of latent class growth model-derived Glasgow Coma Scale trajectories with in-hospital mortality in intracerebral hemorrhage].

Zhonghua yi xue za zhi·2026
Same author

[Real-time localization for port-implanted catheter tip by echocardiographic guidance].

Zhonghua yi xue za zhi·2024
Same author

[The role and molecular mechanism of pyroptosis in bronchiolitis obliterans].

Zhonghua er ke za zhi = Chinese journal of pediatrics·2023
Same author

Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2015
Same author

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2014
Same author

A longitudinal study of the impact of interviews on medical school admissions in Taiwan.

Evaluation & the health professions·2010

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Medical Research Design

Background:

  • Accurate sample size estimation is crucial for clinical trials but often hampered by uncertainty in treatment effects and variability.
  • Existing methods primarily focus on continuous outcomes, leaving a gap for binary response variables where mean and variance are not distinct.
  • The European Union's Note for Guidance emphasizes the importance of robust sample size determination in clinical research.

Purpose of the Study:

  • To develop a method for sample size re-estimation in clinical trials with binary response variables.
  • To address the complexities of binary data where mean and variance are interdependent.
  • To propose a design that maintains trial blinding during sample size adjustments.

Main Methods:

Related Experiment Videos

  • A simple stratification strategy is employed to verify and update initial assumptions on response rates.
  • The proposed design allows for re-estimation of sample size using interim data.
  • Blinding of the clinical trial is preserved throughout the sample size adjustment process.

Main Results:

  • The method effectively handles binary response variables, which are more challenging than continuous ones.
  • Simulation results indicate a minimal impact on Type I error rates.
  • The approach demonstrates sound decision-making characteristics for sample size adjustments.

Conclusions:

  • The presented design offers a practical solution for sample size re-estimation in binary clinical trials.
  • Maintaining blinding during sample size adjustments is feasible and crucial for trial integrity.
  • This methodology enhances the efficiency and reliability of clinical trial planning and execution.